ALBME

FDA Announces Public Workshop to Reconsider Mandatory Prescriber Education for Opioids

The U.S. Food & Drug Administration is reconsidering the need for mandatory opioid prescriber education through the Opioid Analgesic (OA) Risk Evaluation and Mitigation Strategy (REMS).  

The agency announced a two-day public workshop “Reconsidering Mandatory Opioid Prescriber Education Through a Risk Evaluation and Mitigation Strategy (REMS) in an Evolving Opioid Crisis” to give stakeholders an opportunity to provide input on aspects of the current opioid crisis that could be mitigated in a measurable way by requiring mandatory prescriber education as part of a REMS.

For more information, see FDA In Brief: FDA Announces Public Workshop to Reconsider Mandatory Prescriber Education for Opioids | FDA